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INTRODUCTION
Pancreatic  cancer  is  one  of  the  most  aggressive 
human malignancies and the fourth leading cause 
of  cancer  death  in  Europe  and  North  America 
(Klapman  and  Malafa,  2008).  Patients  with  this 
tumor  have  a  median  survival  time  of  6  months 
after initial diagnosis and a 5-year survival rate of 
only 2% (Tomaino et al., 2007). Despite considerable 
development  in  sophisticated  imaging  techniques 
and  cytological  examination,  pancreatic  cancer  is 
most often diagnosed late in the course of the dis-
ease, after local spread and distant metastases have 
occurred. Only in a minority of cases is the diagno-
sis made at a very early stage, when curative surgery 
might  significantly  ameliorate  the  5-year  survival 
rate.  Furthermore,  surgical  therapy  is  frequently 
not  curative.  These  facts  make  pancreatic  cancer 
extremely difficult to treat. An understanding of the 
molecular basis of transformation into a malignant 
tumor of the pancreas may provide a basis for the 
development of more effective strategies for the pre-
vention, diagnosis, and treatment of this cancer.
It has been suggested that ras oncogenes play a 
central role in the development of certain malignan-
cies (Dunn et al., 2005). The family of ras protoon-
cogenes consists of three genes: K-ras, N-ras, and 
H-ras. While wildtype cellular proteins in humans 
play a vital role in normal tissue signalling, mutated 
genes are potent oncogenes that play a role in many 
human cancers. Among ras genes, K-ras is the most 
common target of mutations, while defects in N-ras 
and H-ras are found less frequently.
The  K-ras  gene  encodes  the  human  cellular 
homolog of a transforming gene isolated from the 
Kirsten  rat  sarcoma  virus.  It  is  one  of  the  most 
activated oncogenes, with 17% to 25% of all human 
tumors  harboring  an  activating  K-ras  mutation 
(Dunn  et  al.,  2005).  Critical  regions  of  the  K-ras 
gene  for  oncogenic  activation  include  codons  12, 
13, 59, 61, and 63. These activating mutations cause 
protein  to  accumulate  in  the  active  GTP-bound 
state  by  impairing  intrinsic  GTPase  activity  and 
conferring resistance to GTPase-activating proteins. 
The mutations therefore result in the expression of 
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altered protein products that are capable of trans-
forming cells into a malignant phenotype through 
maintaining  of  the  constitutive  transmission  of  a 
positive signal for cell growth.
Mutations in the K-ras gene were found to be 
related  to  the  development  of  pancreatic  cancer 
and are considered to be early molecular events in 
pancreatic tumorigenesis (Hezel et al., 2006). The 
K-ras mutations are detected with a frequency of 75 
to 100% in pancreatic cancer tissue (Mu et al., 2004). 
Codon 12 of the K-ras gene is by far the most com-
mon site of ras activation in human malignancies, 
with the highest incidence found in ductal adeno-
carcinoma of the pancreas (Moore et al., 2001). The 
high prevalence of point mutations in the K-ras gene 
in pancreatic tumors suggests that K-ras mutation 
detection might be used in future screening proto-
cols for pancreatic cancer. Additionally, activation 
of K-ras has been recognized in microdissected foci 
of pancreatic intraepithelial neoplasia, the precursor 
lesion of pancreatic cancer. Mutations in the K-ras 
gene are also associated with more aggressive, recur-
rent, and metastatic tumors; they therefore seem to 
be an important target for novel anti-cancer thera-
pies (Morioka et al., 2004; Kim et al., 2006).
The aim of this study was to analyze the status 
of K-ras codon 12 mutation in the pancreatic tissue 
of  Serbian  patients  with  pancreatic  cancer,  inves-
tigate the correlation between the presence of the 
mutation and histopathological findings, and assess 
whether the presence of the mutation might be used 
as a molecular marker in future screening protocols 
for pancreatic cancer.
MATERIALS AND METHODS
The study encompassed 40 patients (24 male and 
16  female,  age  42-67  years)  who  underwent  par-
tial  duodenopancreatectomy  for  ductal  adenocar-
cinoma of the pancreas at the First Surgical Clinic 
of the Clinical Center of Serbia. Written informed 
consent was obtained from all study patients and the 
investigation was approved by the hospital’s ethical 
committee. Prior to surgical procedure, clinical di-
agnosis of pancreatic cancer in all patients was made 
based on detailed clinical examinations, abdominal 
ultrasound  examination,  and  spiral  computed  to-
mography (CT) scan. The stage of the cancer was 
determined using TNM Classification of Malignant 
Tumors,  which  is  based  on  criteria  proposed  by 
the American Joint Committee on Cancer (AJCC) 
(Greene et al., 2002).
The tissue samples used in this study were ob-
tained during the surgical procedure and were avail-
able as fresh tissue samples in 20 cases and as paraf-
fin-embedded tissue sections in 20 cases. The fresh 
tissue samples were obtained on surgery and kept 
in isotonic sodium chloride solution prior to DNA 
extraction.  The  paraffin-embedded  tissue  sections 
were cut into slices, the blade being replaced after 
each block was cut to prevent carryover of DNA be-
tween sections.
Phenol/chloroform extraction of DNA was per-
formed on both paraffin-embedded tissue sections 
and fresh tissue slices. Prior to extraction, the sec-
tions  of  paraffin-embedded  tissue  were  deparaf-
finized through washing, twice with 1 mL of xylol, 
twice with 1 mL of absolute ethanol, and once with 
1 mL of 70% ethanol. After each wash, the mixture 
was subjected to vortexing, centrifugation at 13000 
rpm for 5 min, and removal of the supernatant. The 
final pellets of deparaffinized tissues and slices of 
fresh tissues (50-100 mg) were diluted in 50 mmol/L 
Tris-HCl, pH 8.5, and subjected to overnight diges-
tion at 55°C by proteinase K (20 mg/mL). After over-
night digestion, 2.4 mL of phenol was added and the 
mixture centrifuged for 5 min at 3000 rpm at 10°C. 
After transferring the supernatant to a new tube, 2.4 
mL of phenol/chloroform/isoamyl alcohol (25: 24: 
1) solution was added and the mixture centrifuged 
for 5 min at 3000 rpm at 10°C. The supernatant was 
then transferred to a new tube, after which 2.4 mL 
of chloroform/isoamyl alcohol (24: 1) solution was 
added and the mixture centrifuged for 5 min at 3000 
rpm at 10°C. After again transferring the superna-
tant to a new tube, 25 μL of 3 M sodium acetate 
and 5 mL of ethanol were added and the mixture 
incubated at -20°C overnight. The mixture was then 
washed in 2 mL of 70% ethanol and the pellet dried. 
The obtained DNA pellets were resuspended in 100 
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Detection of K-ras codon 12 mutation was per-
formed by the polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP) tech-
nique. The PCR amplification of the part of the K-
ras gene that contains codon 12 was performed with 
the primers 5’-TCAAAGAATGGTCCTGG*ACC-3’ 
and  5’-ACTGAATATAAACTTGTGGTAGTTGG
AC*CT-3’  (*-mismatch  nucleotide)  to  produce  a 
157 bp-long fragment. Both primers introduce the 
recognition site for BstNI endonuclease, while the 
presence of K-ras codon 12 mutation abolishes the 
recognition site created by the second primer (Fig. 
1). The amplification procedure was performed in 
the  following  reaction  mixture:  15  mM  Tris-HCl, 
pH 8.0, 50 mM KCl, 2.5 mM MgCl2, 0.2 mM each 
dNTP, 10 pmol of each primer, 1 U of Taq polymerase 
FIREPol (Solis BioDyne), and approximately 250 ng 
of DNA. Amplification was performed according to 
the following program: initial denaturation at 94°C 
for 5 min; 35 cycles consisting of 94°C for 1 min, 
55°C for 1 min, and 72°C for 1 min; and final elon-
gation at 72°C for 10 min.
The fragments obtained by PCR amplification 
were subjected to reamplification according to the 
same protocol, but with 1 μL of the PCR product 
used as a template instead of DNA. Both amplified 
and reamplified fragments were subjected to restric-
tion enzyme cleavage by endonuclease BstNI (New 
England  BioLabs)  at  60ºC  overnight.  Digestion 
products were analyzed by electrophoresis on 10% 
polyacrylamide gels, followed by silver staining of 
the gels (Radojković and Kušić, 2000). Upon visual-
ization of bands on polyacrylamide gels, the 143-bp 
band depicts the presence of the mutant allele, while 
the 114-bp band depicts the presence of the normal 
allele (Fig. 2).
RESULTS
After histopathological analysis, a clinical diagno-
sis of pancreatic cancer was confirmed in 38 of 40 
patients included in the study, while in two patients 
a diagnosis of chronic pancreatitis was established 
(Table 1).
Detection of K-ras codon 12 mutation by PCR-
RFLP  analysis  was  successfully  performed  for  all 
tissue samples. Of 38 analyzed tumor samples, K-ras 
codon 12 mutation was present in 25 (66%), while 
Fig. 1. Design of the PCR-RFLP method for detection of K-ras 
codon 12 mutation.
Fig. 2. Analysis by PCR-RFLP of K-ras codon 12 mutation on 
10% polyacrylamide gels. 1 - PCR product; 2, 3, 5, 8, 9, 12 - car-
riers of normal K-ras codon 12 allele; 4, 6, 7, 10, 11, 13 - carriers 
of mutant K-ras codon 12 allele.
Table 1. Histopathological findings and distribution of K-ras codon 12 mutation.
number (%) k-ras codon 12 mutation-positive (%) k-ras codon 12 mutation-negative (%)
subjects 40 (100) 25 (62) 15 (38)
histopathological finding
pancreatic carcinoma 38 (95) 25 (66) 13 (34)
chronic pancreatitis 2 (5) 2 (100)A. NIKOLIĆ ET AL. 626
in 13 (34%) only the normal allele was detected. The 
mutation was not detected in either of the patients 
with chronic pancreatitis. The distribution of K-ras 
codon 12 mutation did not differ among patients 
in respect to age or gender (Table 2). Carriers of K-
ras codon 12 mutation were more frequent among 
patients  with  advanced  tumor  stages  T3  and  T4 
(64%),  as  well  as  among  patients  with  regional 
lymph node metastasis (70%).
DISCUSSION
In order to reduce mortality and improve survival 
in the management of pancreatic cancer, it is crucial 
to identify sensitive and specific diagnostic markers 
for detection of the disease at a surgically resectable 
stage. The preoperative assessment algorithm most 
commonly consists of imaging analysis, cytological 
analysis, and determination of biomarker levels in 
the serum. Since there is no definite consensus on 
the  best  approach,  the  choice  of  diagnostic  tech-
niques and biomarkers, as well as the criteria that 
are used to stratify patients, are quite variable. The 
most  commonly  used  serum  markers  for  pancre-
atic cancer are carbohydrate antigen 19-9 (CA19-9) 
and carcinoembryonic antigen (CEA), but they are 
used only in combination with imaging techniques 
and  cytological  analysis  for  diagnostic  purposes 
(Freelove and Walling, 2006). Although the develop-
ment of modern imaging techniques with improved 
resolution  has  allowed  for  the  better  preoperative 
staging  of  patients  with  pancreatic  cancer,  exist-
ing biomarkers are not adequate as early detection 
markers for this disease due to low sensitivity and/
or  specificity.  Numerous  new  molecular  markers 
(DNA-,  RNA-,  and  protein-based)  are  currently 
being investigated as potential diagnostic tools for 
pancreatic cancer, but they need validation in large 
scale studies before they can be used in clinical set-
tings (Liang et al., 2009).
Table 2. Characteristics of patients and distribution of K-ras codon 12 mutation.
number (%) k-ras codon 12 mutation-positive (%) k-ras codon 12 mutation-negative (%)
subjects 38 (100) 25 (66) 13 (34)
age
≤ 60 10 (26) 7 (70) 3 (30)
> 60 28 (74) 18 (64) 10 (36)
gender
male 23 (61) 16 (70) 7 (30)
female 15 (39) 9 (60) 6 (40)
Tumor stage
T1 1 (3) 1 (100)
T2 4 (10) 4 (100)
T3 32 (84) 20 (62) 12 (38)
T4 1 (3) 1 (100)
Regional lymph nodes
N0 8 (21) 4 (50) 4 (50)
N1 30 (79) 21(70) 9 (30)K-RAS MUTATION IN PANCREATIC CANCER 627
In spite of extensive research efforts, the poten-
tial value of K-ras codon 12 mutation as a diagnos-
tic tool in clinical practice remains uncertain. The 
presence of K-ras mutation in the pancreatic tissue 
usually indicates either the presence of a premalig-
nant lesion or early stage pancreatic cancer. It has 
therefore been suggested that this marker might be 
potentially valuable in early detection of pancreatic 
malignancy (Welsch et al., 2007). The aim of our 
study  was  to  investigate  the  potential  use  of  this 
molecular marker in Serbian patients with pancre-
atic cancer. The mutation was detected in 66% of 
patients  with  pancreatic  cancer,  which  is  slightly 
lower than in most studies, where K-ras mutation 
incidence  in  pancreatic  cancers  was  estimated  to 
be 75 to 100% (Hruban et al., 1993; Kubrusly et al., 
2002; Liu et al., 2003; Ren et al., 2004). However, 
considering that all patients included in our study 
were diagnosed with pancreatic cancer at a surgi-
cally resectable tumor stage and that the mutation 
was present in two thirds of them, introduction of 
K-ras codon 12 mutation analysis as part of diag-
nostic  procedures  in  pancreatic  cancer  should  be 
seriously considered.
The  crucial  limitation  in  detection  of  K-ras 
codon 12 mutation in pancreatic tissue is sensitiv-
ity of the method used for its analysis. Since K-ras 
mutation  is  usually  present  in  a  relatively  small 
number  of  cells  in  precancerous  lesions  or  early 
tumor stages, its presence in DNA extracted from 
tissue sections is detectable only in traces. Sensitivity 
of the method can additionally be affected by the 
quantity  and  quality  of  DNA  extracted  from  tis-
sue sections. In general, DNA extracted from fresh 
tissue sections is of better yield and higher quality 
than DNA extracted from paraffin-embedded tis-
sue sections. On the other hand, paraffin-embedded 
tissue sections can be kept for long periods of time 
and are valuable as a source of DNA for retrospec-
tive studies.
In  this  study,  the  presence  of  mutation  was 
detected by the PCR-RFLP method, whose sensitiv-
ity was increased by reamplification of PCR frag-
ments prior to RFLP analysis. As codon 12 mutation 
encompasses  different  nucleotide  changes  at  this 
position in the K-ras gene, the PCR-RFLP method 
was designed for detection of any nucleotide change 
within the given nucleotide triplet, which eliminates 
the influence of codon 12 variability and existing 
ethnic differences (Hayashi et al., 1996). In addition 
to reamplification, increased sensitivity and speci-
ficity of PCR-based methods used for the detection 
of  K-ras  codon  12  mutation  in  pancreatic  tissue 
could also be achieved by application of nested PCR 
or performing a whole genome amplification prior 
to PCR. Although highly specific and reliable, the 
PCR-RFLP method is not sufficiently sensitive for 
diagnostic detection of K-ras codon 12 mutation, 
and the possibility remains that in some patients the 
amount of mutated DNA may be not be detectable 
by this method. More sensitive techniques (such as 
DNA sequencing) should therefore be applied for K-
ras codon 12 mutation detection in future diagnostic 
protocols for pancreatic cancer.
Since the presence of mutation in the K-ras gene 
indicates a preneoplastic condition or cancer at an 
early stage, this test might be used to detect early 
pancreatic cancer and differentiate pancreatic cancer 
from chronic pancreatitis. In this study, the muta-
tion was not present in either of the two patients 
with chronic pancreatitis, who unnecessarily under-
went surgery. However, chronic pancreatitis can be 
positive for the mutation in the absence of cancer, 
while pancreatic cancer does not necessarily have it, 
as was the case with 34% of patients with pancreatic 
cancer in this study (Pugliese et al., 2001; Mu et al., 
2004; Ren et al., 2004; Marchese et al., 2006). It fol-
lows that detection of K-ras codon 12 mutation in 
chronic  pancreatitis  and  pancreatic  cancer  is  not 
informative enough to differentiate between the two 
diseases, but could serve as one of the parameters in 
setting the diagnosis of pancreatic cancer.
Molecular detection of K-ras mutation in pan-
creatic  cancer  management  can  also  be  used  for 
staging of the disease (Lohr et al., 2005; Kim et al., 
2006).  In  this  study,  a  higher  frequency  of  K-ras 
codon 12 mutation was observed in patients with 
advanced  tumor  stages  and  regional  lymph  node 
metastases, which correlates with the finding that 
K-ras mutations are associated with more aggres-
sive, recurrent, and metastatic tumors (Morioka et 
al., 2004; Kim et al., 2006).A. NIKOLIĆ ET AL. 628
In addition to analysis of the presence of K-ras 
gene mutation in pancreatic tissue, this molecular 
marker can also be detected in pancreatic juice and 
blood  plasma,  since  small  amounts  of  DNA  are 
released from tumor cells due to necrosis (Castells et 
al., 1999; Sorenson, 2000; Trumper et al., 2002; Jiao 
et al., 2007). Although its sensitivity is relatively low, 
this approach to molecular monitoring of pancreatic 
cancer is highly specific and has potential for future 
application  in  diagnostic  and  prognostic  clinical 
practice (Castells et al., 1999; Sorenson, 2000; Jiao 
et al., 2007).
Our  study  confirms  that  K-ras  mutation  is 
present with a high frequency in patients with pan-
cretic cancer, especially at advanced tumor stages. 
Although  the  finding  of  K-ras  point  mutation  in 
cytology  or  biopsy  samples  from  pancreatic  mass 
does not specifically confirm the diagnosis of pan-
creatic cancer, it can increase the sensitivity of exist-
ing techniques and hence be used as an adjunct to 
imaging and cytological analyses in pancreatic can-
cer diagnosis. Further studies are needed to define 
the value of K-ras mutation screening in patients 
with other evidence suggesting the presence of pan-
creatic cancer. The ultimate goal is to detect pancre-
atic cancer at an early stage and avoid unnecessary 
duodenopancreatectomies for chronic pancreatitis.
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АНАЛИЗА МУТАЦИЈЕ У КОДОНУ 12 ГЕНА K-RAS У ПАНКРЕАСНОМ ТКИВУ
ПАЦИЈЕНАТА СА КАРЦИНОМОМ ПАНКРЕАСА
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Ово  истраживање  је  имало  за  циљ  да  се 
анализира  присуство  мутације  у  кодону  12 
гена  K-ras  у  панкреасном  ткиву  пацијената 
са  карциномом  панкреаса  и  да  се  процени  да 
ли  ова  мутација  представља  потенцијални 
молекуларни  маркер  за  карцином  панкреаса  у 
српској популацији. Истраживање је обухватило 
анализу 40 узорака ткива панкреаса пацијената 
са клиничком дијагнозом карцинома панкреаса. 
Присуство  мутације  у  кодону  12  гена  K-ras 
анализирано је методом PCR-RFLP (polymerase 
chain reaction - restriction fragment length poly-
morphism).  Резултати  истраживања  указују  да 
је  мутација  у  кодону  12  гена  K-ras  у  ткиву 
панкреаса присутна са високом учесталошћу (66 
%) код пацијената са карциномом панкреаса.